Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.49−0.10 (-6.29%)

Close on Nov 12, 2026Market cap $139.64MP/E –Yield –

Innate Pharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Innate Pharma's total debt was €2.10K at Jun 30, 2026.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	€2.10K	–

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Revenue growth-55.2% · median -38.4%

Operating margin-599.8% · median -1140.6%

Advertisement
300 × 250

See a number that looks wrong?